肠道托皮拉马特治疗在耐火状态的患者中
Selda Keskin-Güler1, Ömer Karadaş2, Murat Mert Atmaca3
1University of Health Sciences, Ankara Training and Research Hospital, Department of Neurology, Ankara, Turkey.
Epilepsy research
|April 5, 2025
概括
托皮拉 (TPM) 有效治疗耐火性 (RSE),这种疾病的死亡率很高. 这项研究发现TPM耐受性良好,并成功改善RSE患者的治疗结果.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 耐药性状态 (RSE) 具有显著的死亡风险,尽管有治疗方法.
- 托皮拉 (TPM) 是一种广谱抗药物 (ASM),具有潜在的神经保护和抗炎性质.
- 研究TPM在RSE中的疗效对于改善患者的治疗结果至关重要.
研究的目的:
- 评估托皮拉 (TPM) 在治疗耐火状态 (RSE) 的疗效.
- 评估TPM对RSE患者死亡率的影响.
- 确定RSE中肠道TPM治疗的安全性和耐受性概况.
主要方法:
- 这是一项回顾性多中心研究,涉及土耳其六家医院的60名成年RSE患者.
- 对人口统计数据,发作分类,病因学和TPM治疗参数 (加载和维持剂量) 的分析.
- 评估与TPM使用相关的治疗结果,预后,并发症和死亡率.
主要成果:
- 作为第三线ASM,TPM被给予200-500mg二次加载剂量,其次是100-200mg/天的维持剂量.
- 在22名患者中,TPM被认为是成功的,在23名患者中可能是成功的,在15名患者中是不成功的. 副作用导致6名患者停止治疗.
- 死亡率预测因素包括年龄较大,没有,未能终止RSE,以及急性症状病因. 成功的TPM治疗与更短的住院时间相关.
结论:
- 肠道托皮拉 (TPM) 治疗显示出良好的安全性,并且在RSE患者中耐受良好.
- TPM在治疗耐火性状态 (RSE) 方面是有效的,有助于改善患者的治疗结果.
- 这项研究是第一个报告使用高剂量和低剂量口服TPM终止SE的研究.
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
266
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
266
Antiepileptic Drugs: GABAergic Pathway Potentiators
303
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
303
Antiepileptic Drugs: Potassium Channel Activators
138
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
138
Psychosis: Goals of Pharmacotherapy
101
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
101
Antiepileptic Drugs: Sodium Channel Blockers
323
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
323
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
207
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
207


